Reproductive Health Drugs Panel Holds On To Hager For A New Term
This article was originally published in The Tan Sheet
Executive Summary
House members critical of FDA's "not approvable" decision on OTC emergency contraception were unsuccessful in blocking the reappointment of David Hager, MD, University of Kentucky, to the agency's Reproductive Health Drugs Advisory Committee
You may also be interested in...
Crawford Nomination Woes Grow With Coburn Hold, Hager Letter
FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination
FDA Advisory Committee Panelists React To Plan B “Not Approvable” Letter
Four current and former FDA panelists participated in May 7 interviews with "The Tan Sheet" to discuss FDA's "not approvable" letter regarding Barr Labs' OTC switch application for the Plan B (levonorgestrel) emergency contraceptive. Below are excerpts from conversations with Nonprescription Drugs Advisory Committee member Alastair Wood, MD, Vanderbilt University Medical Center; NDAC guest consultant James Trussell, PhD, Princeton University; Reproductive Health Drugs Advisory Committee member David Hager, MD, University of Kentucky; and former NDAC Chairman Randy Juhl, PhD, University of Pittsburgh.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC